CJC-1295 no DAC and Sermorelin are each a copy of GHRH.
GHRH is the signal that tells your pituitary to release its own growth hormone.
Same target, different schedules: CJC-1295 no DAC daily to 2x daily; Sermorelin daily/nightly.
| Comparison | CJC-1295 no DAC (Mod GRF 1-29) Mod GRF 1-29 · Modified GRF 1-29 | Sermorelin GRF 1-29 · Geref |
|---|---|---|
| How it works | How it works This is the same GHRH copy as CJC-1295 with DAC, minus the anchor that makes it last. That one difference changes everything about how it behaves. | How it works Sermorelin is a shortened copy of GHRH, containing the first 29 amino acids, which is the smallest piece that still works. |
| What it is | A short-acting growth-hormone pulse, usually paired with ipamorelin. | A gentle shot that prompts your body to make more of its own growth hormone. |
| Status | Research only | In clinical useCompounded |
| Typical dose | 0.1 mg per dose | 0.2–0.5 mg per dose |
| How often | Daily to 2x daily | Daily/nightly |
| Stays active | ~30 minutes | ~10-20 minutes |
| Dose comes from | Community practice | Clinical guideline |
| Cycled? | Commonly cycled, usually 8 to 12 weeks on and 4 off Community practice | Not cycled Clinical guideline |
| What it does | ||
| Drug class | GH secretagogue (GHRH) | GH secretagogue (GHRH) |
| Used for | The short-acting version that gives a quick growth-hormone pulse closer to your body's natural rhythm. It is usually paired with ipamorelin for muscle, fat loss, and recovery. | Encourages your body to make more of its own growth hormone for better recovery, deeper sleep, more muscle, and slower aging. A gentler route than injecting growth hormone directly. |
| Receptors hit | — | — |
| Numbers | ||
| Full dose line | 0.1 mg per dose | 0.2 up to 0.5 mg per dose (start low, increase slowly) |
| Why that cycle | Because it clears in about half an hour it produces a pulse rather than a raised baseline, which is the argument users give for needing less of a break than the DAC version. Neither schedule has been tested. | In clinical use it is given nightly and continuously for as long as it is working. The on/off schedules attached to it online come from the research-peptide market, not from how it is prescribed. |
| Weight / effect | Not measured in a trial | Not measured in a trial |
| Chain length | 29 residues | 29 residues |
| Common vial | 5 mg | 5 mg |
| Before you start | ||
| Route | Under the skin (subcutaneous) | Under the skin, at bedtime |
| Do not use if | Active cancer, as a precaution with anything raising growth hormone Pregnancy Banned in drug-tested sport | Known allergy to sermorelin Active cancer, since it raises growth hormone and IGF-1 Pregnancy |
What separates them
Proof behind the dose. Sermorelin has a dose that follows clinical guidelines. CJC-1295 no DAC has a range that comes from community practice, with no published human study behind it.
Legal standing. Sermorelin is approved or in established clinical use. CJC-1295 no DAC is research-only, meaning no regulator has assessed it for use in people.
Staying on it. Sermorelin is taken continuously. CJC-1295 no DAC is normally run in blocks with breaks, though for this one the block length is convention rather than a tested schedule.
What doesn't differ: Neither has a measured effect size from a published trial, so there is no number to rank them on.
What people actually report
CJC-1295 no DAC (Mod GRF 1-29)
- It clears in about half an hour, so it needs frequent dosing.
- It is not approved and is banned in drug-tested sport.
- Spreading hives, face or throat swelling, or trouble breathing
- New lumps or masses
Sermorelin
- Mostly injection-site redness or irritation; generally well tolerated.
- Swelling of the face or throat, trouble breathing, or hives
Side effects are what users and trials report most often, not a complete list. Anything sudden, spreading, or breathing-related is an emergency regardless of which compound caused it.
People also compare
This comparison does not cover cost, long-term safety, or how you personally will respond. Effect figures come from separate trials in different populations and are not always directly comparable to each other. Nothing here is medical advice or a recommendation to use any of these. Talk to a clinician about your own situation.